Verify
Independent lab results
Published results from laboratories that tested peptide products, most obtained by a study team itself and some submitted by buyers; each row's source says which, and a submitted vial's origin is only what the buyer declared, failures included. Every row names the laboratory, the method, when the testing was done, what was expected, what was found, and where it was published, so you can check it.
A seller's own certificate is not a source here, and neither is a result nobody can trace. The table shows no prices, no purchase links and no overall score for any seller: a row is one measurement of one product, not a verdict on a company. Data as of November 2, 2026; 40 results. Rules: methodology. Download: lab-results.json.
The big picture: an April 2026 preprint analysed 6,285 test results on 14 research peptides from 203 companies; 41.6% to 71.1% failed, mostly on the amount in the vial. It reports aggregates, not products, so it is summarised on What lab testing shows rather than added here.
By compound
How many products of each compound published tests cover, and what they found. A product is one vial, pen or pack as sold; a product tested for identity and for content counts once. Results are counted per product, so one failed content test on three vials counts three. A product counts as failed when a test found the wrong molecule, less or more than the label, or contamination; "inconclusive" means the source gave no standard to judge the figure against.
| Compound | Products tested | Published reports | Results by measure (products) | Failed results |
|---|---|---|---|---|
| ACE-031 | 14 | 1 | identity: 14 fail | 14 |
| BPC-157 | 1 | 1 | identity: 1 pass | 0 |
| Epithalon | 2 | 1 | identity: 2 pass | 0 |
| Follistatin-344 | 17 | 1 | identity: 8 fail, 9 pass | 8 |
| GHRP-2 | 2 | 1 | identity: 1 inconclusive, 1 pass | 0 |
| Hexarelin | 1 | 1 | identity: 1 pass | 0 |
| IGF-1 LR3 | 1 | 1 | identity: 1 fail | 1 |
| Melanotan II | 4 | 2 | identity: 4 pass; content: 4 fail; purity: 3 inconclusive | 4 |
| MK-677 | 4 | 1 | identity: 4 pass | 0 |
| Retatrutide | 3 | 1 | identity: 3 pass; content: 3 fail | 3 |
| Semaglutide | 7 | 3 | identity: 2 fail; content: 3 fail, 3 inconclusive, 2 pass; purity: 2 inconclusive; sterility: 3 pass; endotoxin: 3 inconclusive | 5 |
| TB-500 | 1 | 1 | identity: 1 pass | 0 |
What a forged or misleading certificate looks like, with sourced examples: Fake COA red flags. How peptides are made and purified, and which impurities each step can leave: how peptide drugs are made.
Results
| Compound | Seller | Measure | Result | Outcome | Method | Laboratory | Tested | Source |
|---|---|---|---|---|---|---|---|---|
| Semaglutide | Biotech Peptides | content | 3.86 mg expected: 3 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20241 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | content | 7.7 % expected: no share of the powder is stated; the seller claimed at least 99% purity, which is a different measure | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20242 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20243 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | endotoxin | <2.1645 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20244 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | content | 2.77 mg expected: 2 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20245 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | content | 14.37 % expected: no share of the powder is stated; the seller claimed at least 99% purity, which is a different measure | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20246 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20247 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | endotoxin | 8.9511 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20248 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | content | 1.34 mg expected: 1 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20249 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | content | 8.97 % expected: no share of the powder is stated; the seller claimed at least 99% purity, which is a different measure | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 202410 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 202411 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | endotoxin | <2.8658 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 202412 | PMID 39509151; PMID 39093567 |
| Retatrutide | PARTY-04 | identity | retatrutide confirmed in all three expected: retatrutide, as labelled (expected molecular weight 4730.477 Da) | pass | MS | An independent NATA-accredited laboratory, not named in the paper (samples via PEDTest Australia) | 202613 | PMID 42559975 |
| Retatrutide | PARTY-05 | content | 5.13 mg expected: 10 mg of retatrutide per vial, as labelled | fail | MS | An independent NATA-accredited laboratory, not named in the paper (samples via PEDTest Australia) | 202614 | PMID 42559975 |
| Retatrutide | PARTY-06 | content | 19.0 mg expected: 10 mg of retatrutide per vial, as labelled | fail | MS | An independent NATA-accredited laboratory, not named in the paper (samples via PEDTest Australia) | 202615 | PMID 42559975 |
| Retatrutide | PARTY-07 | content | 16.5 mg expected: 10 mg of retatrutide per vial, as labelled | fail | MS | An independent NATA-accredited laboratory, not named in the paper (samples via PEDTest Australia) | 202616 | PMID 42559975 |
| Melanotan II | PARTY-08 | identity | melanotan II confirmed expected: melanotan II, as sold | pass | LC-MS | Department of Clinical Biochemistry, Vendsyssel Hospital (Aalborg University), Denmark | 201417 | PMID 24771717 |
| Melanotan II | PARTY-08 | content | 4.32 to 8.84 mg expected: 10 mg of melanotan II per vial, as each shop claimed | fail | HPLC | Department of Clinical Biochemistry, Vendsyssel Hospital (Aalborg University), Denmark | 201418 | PMID 24771717 |
| Melanotan II | PARTY-08 | purity | unknown impurities 4.1 to 5.9% (two shops); below the quantification limit (one shop) % expected: no stated purity; no pharmacopoeial standard exists for melanotan II | inconclusive | HPLC | Department of Clinical Biochemistry, Vendsyssel Hospital (Aalborg University), Denmark | 201419 | PMID 24771717 |
| Semaglutide | PARTY-09 | content | 101 % expected: 1 mg/mL of semaglutide, as labelled (100%) | pass | HPLC | Novo Nordisk A/S analytical laboratories (CMC Analysis & Characterisation), Denmark | 202520 | PMID 42533250 |
| Semaglutide | PARTY-09 | purity | sum of impurities 1.3% % expected: no limit stated for a compounded product; the originator measured 3.2 to 3.4% in the same study | inconclusive | HPLC | Novo Nordisk A/S analytical laboratories (CMC Analysis & Characterisation), Denmark | 202521 | PMID 42533250 |
| Semaglutide | PARTY-10 | content | 102 % expected: 1 mg/mL of semaglutide, as labelled (100%) | pass | HPLC | Novo Nordisk A/S analytical laboratories (CMC Analysis & Characterisation), Denmark | 202522 | PMID 42533250 |
| Semaglutide | PARTY-10 | purity | sum of impurities 2.5% % expected: no limit stated for a compounded product; the originator measured 3.2 to 3.4% in the same study | inconclusive | HPLC | Novo Nordisk A/S analytical laboratories (CMC Analysis & Characterisation), Denmark | 202523 | PMID 42533250 |
| Follistatin-344 | PARTY-11 | identity | follistatin 344 present in 9 of the 17 products expected: follistatin 344, as each product was sold (the paper's E. coli FS344 standard runs at about 43.5 kDa) | pass | immunoblot identity only; does not measure purity or amount | Doping Control Laboratory Seibersdorf (Seibersdorf Labor GmbH), Austria | 201924 | PMID 31758732 |
| Follistatin-344 | PARTY-12 | identity | no follistatin in 8 of the 17 products: no protein larger than 20 kDa expected: follistatin 344, as each product was sold (the paper's E. coli FS344 standard runs at about 43.5 kDa) | fail | SDS-PAGE identity only; does not measure purity or amount | Doping Control Laboratory Seibersdorf (Seibersdorf Labor GmbH), Austria | 201925 | PMID 31758732 |
| BPC-157 | PARTY-13 | identity | BPC 157 confirmed expected: BPC 157 (GEPPPGKPADDAGLV), as printed on the vial | pass | LC-MS | Sports Medicine Research and Testing Laboratory, Salt Lake City, Utah, USA | 201626 | PMID 28035768 |
| TB-500 | PARTY-14 | identity | Ac-LKKTETQ (N-acetylated thymosin beta-4 17-23) only; no full-length thymosin beta-4 expected: TB-500 as this encyclopedia defines it: the acetylated LKKTETQ fragment of thymosin beta-4 (the product itself gave no sequence or molecular weight) | pass | LC-MS | Doping Control Laboratory (DoCoLab), Ghent University, Belgium | 201227 | PMID 22962027 |
| MK-677 | PARTY-15 | identity | ibutamoren detected in all 4 products whose label declared it expected: ibutamoren (MK-677), as declared on each product's label | pass | LC-MS | LGC, Fordham, Cambridgeshire, UK | 202028 | PMID 32748554 |
| ACE-031 | PARTY-16 | identity | no ACE-031 in 12 of the 14 products: full-length activin receptor IIB without the Fc fragment expected: ACE-031 (ramatercept), as each product was sold: an activin receptor IIB fragment fused to the Fc part of human IgG1 | fail | LC-MS | Doping Control Laboratory Seibersdorf (Seibersdorf Labor GmbH), Austria | 202529 | PMID 40312924 |
| ACE-031 | PARTY-17 | identity | no ACE-031 in 1 of the 14 products: follistatin 344 instead expected: ACE-031 (ramatercept), as each product was sold: an activin receptor IIB fragment fused to the Fc part of human IgG1 | fail | immunoblot identity only; does not measure purity or amount | Doping Control Laboratory Seibersdorf (Seibersdorf Labor GmbH), Austria | 202530 | PMID 40312924 |
| ACE-031 | PARTY-18 | identity | no ACE-031 in 1 of the 14 products: no protein found expected: ACE-031 (ramatercept), as each product was sold: an activin receptor IIB fragment fused to the Fc part of human IgG1 | fail | SDS-PAGE identity only; does not measure purity or amount | Doping Control Laboratory Seibersdorf (Seibersdorf Labor GmbH), Austria | 202531 | PMID 40312924 |
| Hexarelin | PARTY-19 | identity | hexarelin found, as labelled expected: hexarelin, as printed on the vial | pass | LC-MS | Cologne Doping Control Laboratory (Institute of Biochemistry, German Sport University Cologne), Germany | 200932 | PMID 21204286 |
| GHRP-2 | PARTY-20 | identity | GHRP-2 found (about 50 µg per tablet) expected: GHRP-2, as named on the label of an over-the-counter tablet supplement | pass | LC-MS | Cologne Doping Control Laboratory (Institute of Biochemistry, German Sport University Cologne), Germany | 200933 | PMID 21204286 |
| GHRP-2 | PARTY-21 | identity | GHRP-2 found (about 9 mg per ampoule) expected: 'active GHRP-2 ester Z11', as named on the label of an over-the-counter drinking solution | inconclusive | LC-MS | Cologne Doping Control Laboratory (Institute of Biochemistry, German Sport University Cologne), Germany | 200934 | PMID 21204286 |
| Epithalon | PARTY-22 | identity | Epitalon (AEDG) confirmed expected: Epitalon, sequence AEDG, as printed on the vial ('50 mg Epitalon') | pass | LC-MS | Official Medicines Control Laboratory, Scientific Institute of Public Health (WIV-ISP, now Sciensano), Brussels, Belgium | 201435 | PMID 25535022 |
| Epithalon | PARTY-23 | identity | Epitalon (AEDG) confirmed expected: Epitalon, as printed on the container ('EPITALON, food supplement', 3 mg of peptide per tablet) | pass | LC-MS | Official Medicines Control Laboratory, Scientific Institute of Public Health (WIV-ISP, now Sciensano), Brussels, Belgium | 201436 | PMID 25535022 |
| IGF-1 LR3 | PARTY-24 | identity | no IGF-1 of any form; epidermal growth factor (EGF, 6215.9 Da) found instead expected: long R3 IGF-1, as printed on the vial ('reconbinant IGF-1 long R3', misspelled on the label) | fail | LC-MS | Official Medicines Control Laboratory, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium | 201437 | PMID 27390261 |
| Melanotan II | PARTY-25 | identity | melanotan II confirmed expected: melanotan II, as printed on the vial ('Melanotan II', 10 mg) | pass | LC-MS | Laboratory of Clinical, Forensic and Environmental Toxicology, University Hospital of Liège, Belgium | 202438 | PMID 39302005 |
| Melanotan II | PARTY-25 | content | 2.61 mg expected: 10 mg of melanotan II per vial, as printed on the label | fail | HPLC | Laboratory of Clinical, Forensic and Environmental Toxicology, University Hospital of Liège, Belgium | 202439 | PMID 39302005 |
| Semaglutide | PARTY-26 | identity | no semaglutide; insulin glulisine found instead expected: semaglutide, as the pens were presented (falsified Ozempic pre-filled pens) | fail | LC-MS | CVUA Karlsruhe (Chemisches und Veterinäruntersuchungsamt Karlsruhe), Germany | November 202340 | CVUA Karlsruhe report |
Two methods here show identity only: an immunoblot (western blot) shows whether a protein that a specific antibody recognises is present at the expected size, and an SDS-PAGE gel with a protein stain shows whether any protein of that size is there at all. Neither measures purity or how much is in the vial, which takes HPLC or mass spectrometry, so a row using either is an identity result and is marked so.
Notes on each result
- LR-0001: Measured 3.86 mg (SD 0.14) against 3 mg on the label: 28.56% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0002: Semaglutide made up 7.7% (SD 0.28) of the powder in the vial by weight (3.86 mg of 50.1 mg). The paper's table heads this column 'measured purity' beside the 99% claimed, but its text calls the figure the polypeptide concentration, and the chromatogram showed only semaglutide, with no peptide-like impurities. So this is not the chromatographic purity a research-grade '99%' claim means: the rest of the powder is undeclared material the paper did not identify. The measurement stands; the comparison with 99% is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0003: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0004: Reported as below 2.1645 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>) — an upper bound, not a measured level, although the paper's abstract describes endotoxin as detected in all samples. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0005: Measured 2.77 mg (SD 0.12) against 2 mg on the label: 38.69% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0006: Semaglutide made up 14.37% (SD 0.63) of the powder in the vial by weight (2.77 mg of 19.3 mg). The paper's table heads this column 'measured purity' beside the 99% claimed, but its text calls the figure the polypeptide concentration, and the chromatogram showed only semaglutide, with no peptide-like impurities. So this is not the chromatographic purity a research-grade '99%' claim means: the rest of the powder is undeclared material the paper did not identify. The measurement stands; the comparison with 99% is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0007: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0008: Endotoxin measured at 8.9511 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>), the highest of the three; the paper says it indicates potential environmental contamination during production. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0009: Measured 1.34 mg (SD 0.07) against 1 mg on the label: 33.58% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0010: Semaglutide made up 8.97% (SD 0.51) of the powder in the vial by weight (1.34 mg of 14.9 mg). The paper's table heads this column 'measured purity' beside the 99% claimed, but its text calls the figure the polypeptide concentration, and the chromatogram showed only semaglutide, with no peptide-like impurities. So this is not the chromatographic purity a research-grade '99%' claim means: the rest of the powder is undeclared material the paper did not identify. The measurement stands; the comparison with 99% is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0011: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0012: Reported as below 2.8658 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>) — an upper bound, not a measured level, although the paper's abstract describes endotoxin as detected in all samples. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0013: Identity was confirmed by molecular weight in all three products sold as retatrutide. The three products came from sellers the letter does not name; this row summarises all three, so PARTY-04 stands for that group, not for one seller. A buyer submitted each sample, so where each vial came from is self-declared. Test date: The letter does not date the analyses. It was received by the journal on July 15, 2026, so the testing was done on or before then; recorded as 2026, the year of the letter.
- LR-0014: Sample 1 of the letter's Table 1: 5.13 mg against 10 mg on the label (51.3% of the labelled content). The letter says only that peptide content was quantified to estimate the amount per vial; the method is recorded as mass spectrometry because identity was confirmed by molecular weight. A reader dosing by the label would receive about half the intended amount. A buyer submitted the sample, so its origin is self-declared. Test date: The letter does not date the analyses. It was received by the journal on July 15, 2026, so the testing was done on or before then; recorded as 2026, the year of the letter.
- LR-0015: Sample 2 of the letter's Table 1: 19.0 mg against 10 mg on the label (190.0% of the labelled content). The letter says only that peptide content was quantified to estimate the amount per vial; the method is recorded as mass spectrometry because identity was confirmed by molecular weight. A reader dosing by the label would receive far more than the intended amount. A buyer submitted the sample, so its origin is self-declared. Test date: The letter does not date the analyses. It was received by the journal on July 15, 2026, so the testing was done on or before then; recorded as 2026, the year of the letter.
- LR-0016: Sample 3 of the letter's Table 1: 16.5 mg against 10 mg on the label (165.0% of the labelled content). The letter says only that peptide content was quantified to estimate the amount per vial; the method is recorded as mass spectrometry because identity was confirmed by molecular weight. A reader dosing by the label would receive far more than the intended amount. A buyer submitted the sample, so its origin is self-declared. Test date: The letter does not date the analyses. It was received by the journal on July 15, 2026, so the testing was done on or before then; recorded as 2026, the year of the letter.
- LR-0017: Identity was verified by retention time and the abundance ratios of five fragment ions. The study bought vials from three online shops and reports by shop, not by vial; samples counts one per shop, and PARTY-08 stands for the three shops together, not for one seller. Test date: The abstract gives no testing date. The paper was first published online on April 25, 2014, so the analyses were done before then; recorded as 2014, the year of first publication.
- LR-0018: Quantified by LC-UV at 218 nm with a method validated against the guidelines for authorised medicines. Every shop claimed 10 mg per vial; the vials held 4.32 to 8.84 mg, so all fell short. Three shops, one per sample, reported as a range. Test date: The abstract gives no testing date. The paper was first published online on April 25, 2014, so the analyses were done before then; recorded as 2014, the year of first publication.
- LR-0019: Vials from two shops contained unidentified impurities of 4.1 to 5.9%; impurities in the third shop's vials were below the quantification limit. Read as inconclusive because no standard sets a limit for an unapproved product. Test date: The abstract gives no testing date. The paper was first published online on April 25, 2014, so the analyses were done before then; recorded as 2014, the year of first publication.
- LR-0020: Product CP12 in the paper: an injectable compounded semaglutide in a vial from a US outsourcing facility, labelled 1 mg/mL. Before light exposure it measured 1.01 mg/mL (101% of the label). After ICH Q1B light exposure it fell to 0.95 mg/mL (95%), while the originator did not change. The study was funded by, and run in the laboratories of, Novo Nordisk, which makes the originator; read it with that in mind. Test date: The paper does not date the tests. It says the products 'were commercially available for patient use at the time of testing', and its references were accessed on December 11, 2025; recorded as 2025.
- LR-0021: Product CP12: the sum of impurities was 1.3% before light exposure and 5.1% after it; high-molecular-weight proteins rose from <0.3% to 2.6%. As received it was within the originator's own range, so the reading is inconclusive rather than a failure; the change under light is the paper's finding. Manufacturer-funded study, as noted on the content row. Test date: The paper does not date the tests. It says the products 'were commercially available for patient use at the time of testing', and its references were accessed on December 11, 2025; recorded as 2025.
- LR-0022: Product CP13 in the paper: an injectable compounded semaglutide in a vial from a US outsourcing facility, labelled 1 mg/mL. Before light exposure it measured 1.02 mg/mL (102% of the label). After ICH Q1B light exposure it fell to 0.86 mg/mL (86%), while the originator did not change. The study was funded by, and run in the laboratories of, Novo Nordisk, which makes the originator; read it with that in mind. Test date: The paper does not date the tests. It says the products 'were commercially available for patient use at the time of testing', and its references were accessed on December 11, 2025; recorded as 2025.
- LR-0023: Product CP13: the sum of impurities was 2.5% before light exposure and 14.2% after it; high-molecular-weight proteins rose from 0.3% to 14.1%. As received it was within the originator's own range, so the reading is inconclusive rather than a failure; the change under light is the paper's finding. Manufacturer-funded study, as noted on the content row. Test date: The paper does not date the tests. It says the products 'were commercially available for patient use at the time of testing', and its references were accessed on December 11, 2025; recorded as 2025.
- LR-0024: Nine of the 17 products sold as follistatin 344 showed a main band at the FS344 position on SDS-PAGE, and immunoblotting with an anti-follistatin antibody confirmed it was follistatin. All nine also reacted with an anti-His-tag antibody, so they carried a His-tag, a laboratory purification tag the human protein does not have, and all nine held a high share of oligomers (mostly dimers and trimers) 'aside from impurities'. Identity only: an immunoblot shows that an antibody-reactive protein of the expected size is present; it does not measure purity or how much is in the vial, and the paper reports neither. The products came from suppliers in Bulgaria, Canada, China, India, Slovakia, Switzerland, the Netherlands, the UK and the USA, which the paper keeps anonymous (BM01 to BM17); PARTY-11 stands for these nine together, not for one seller. Test date: The paper does not date the analyses. It was published in the November 2019 issue of Drug Testing and Analysis, so the products were tested on or before then; recorded as 2019, the year of publication.
- LR-0025: Eight of the 17 products sold as follistatin 344 contained no protein larger than 20 kDa on SDS-PAGE with Coomassie stain (10 micrograms loaded per lane), so no follistatin. Mass spectrometry found small growth-promoting peptides in some of these 'empty' products, the paper's examples being MGF and GHRP-2; it does not show those data or say which products. Identity only: the gel shows that no protein of follistatin's size was there; it does not identify or measure what the vials held instead. PARTY-12 stands for these eight anonymous suppliers together, not for one seller. Test date: The paper does not date the analyses. It was published in the November 2019 issue of Drug Testing and Analysis, so the products were tested on or before then; recorded as 2019, the year of publication.
- LR-0026: The vial was labelled 'BPC 157, GEPPPGKPADDAGLV'. High-resolution accurate-mass LC-MS/MS found the doubly charged parent ion at m/z 710.3575 against 710.3594 expected (2.7 ppm) and eight fragment ions matching the sequence, each within 10 ppm. The paper reports identity only: it gives no purity and no amount for the vial. Where the vial was bought is unknown. Test date: The paper does not date the analysis. It was first published online on December 29, 2016, so the vial was analysed on or before then; recorded as 2016.
- LR-0027: The sealed vial held about 10 mg of white powder. HPLC with high-resolution (Orbitrap) mass spectrometry showed one main peak of molecular weight 888.49, the N-terminally acetylated LKKTETQ heptapeptide, confirmed by de novo sequencing, NMR and comparison with a synthesised reference; it did not contain full-length thymosin beta-4 (molecular weight 4,963). A slower gradient still showed a single peak, and no other active substance or excipient was detected, but the paper gives no purity figure or amount, so this is an identity result only. A buyer expecting the whole thymosin beta-4 protein would not have received it. Test date: The paper does not date the analysis. It was published online on September 7, 2012, so the vial was analysed on or before then; recorded as 2012.
- LR-0028: Four of the 20 capsule products declared ibutamoren (products 1, 4, 8 and 17, from four different manufacturers); UHPLC with high-resolution accurate-mass MS, against a reference standard, found it in all four. Three of the four were multi-ingredient 'stacks', and two of those held a discrepancy elsewhere: product 8 lacked its declared RAD140 and held undeclared YK11, and product 4 held undeclared RAD140. Ibutamoren was also found, undeclared, in four other products (2, 6, 7 and 14). The paper plots measured amounts against label claims only as a figure, so no amount is recorded here; identity only. PARTY-15 stands for the four manufacturers together, not for one seller. Test date: The paper does not date the analyses. It was first published online in August 2020, so the products were tested on or before then; recorded as 2020.
- LR-0029: Twelve of the 14 products sold as ACE-031 showed a main band at about 58.4 kDa on SDS-PAGE with many other proteins beside it, and an anti-ACVR2B immunoblot confirmed activin receptor IIB was present; neither test can tell ACE-031 from the receptor itself. In-gel tryptic digestion with LC-high-resolution MS found peptides from the receptor's cytoplasmic region and none from the human IgG1 Fc fragment ACE-031 carries, and IdeS protease, which cuts an Fc fusion protein, did not cleave the products, so the paper concludes the 12 held the full-length receptor, not ACE-031. Eleven of the 12 also carried a His-tag (all except BM03). Identity only: no purity or amount was measured. PARTY-16 stands for these 12 anonymous suppliers together, not for one seller. Test date: The paper does not date the analyses. It was published in 2025 (Drug Testing and Analysis volume 17, issue 10; PubMed date May 1, 2025), so the products were tested on or before then; recorded as 2025, the year of publication.
- LR-0030: One product (BM04) showed a different protein profile on SDS-PAGE (about 40.8 kDa), gave no signal on the anti-ACVR2B immunoblot and was identified as follistatin 344 by an anti-follistatin immunoblot. Identity only: an immunoblot shows which antibody-reactive protein is present; it does not measure purity or amount. PARTY-17 is this one anonymous supplier. Test date: The paper does not date the analyses. It was published in 2025 (Drug Testing and Analysis volume 17, issue 10; PubMed date May 1, 2025), so the products were tested on or before then; recorded as 2025, the year of publication.
- LR-0031: One product (BM14) showed no protein on SDS-PAGE with Coomassie stain (about 10 micrograms loaded per lane), so no ACE-031. The paper says mass spectrometry identified ipamorelin in it instead but does not show those data. Identity only: the gel shows that no protein was there; it does not identify or measure what the vial held. PARTY-18 is this one anonymous supplier. Test date: The paper does not date the analyses. It was published in 2025 (Drug Testing and Analysis volume 17, issue 10; PubMed date May 1, 2025), so the products were tested on or before then; recorded as 2025, the year of publication.
- LR-0032: An injection vial labelled hexarelin, obtained by the laboratory from the Anti-Doping Authority of the Netherlands together with vials labelled growth hormone and erythropoietin. Liquid chromatography with mass spectrometry found hexarelin, 'as indicated on their labels'. The paper reports identity only: no amount, purity or sterility for this vial. Where it was bought is unknown. The two vials labelled growth hormone in the same set held no active substance. Test date: The paper reports on 'different confiscated products and legally obtained nutritional supplements' that 'were analyzed in 2009'; recorded as 2009.
- LR-0033: Tablets sold over the counter as a nutritional supplement in Cyprus, labelled to contain GHRP-2 with three amino-acid ingredients. Liquid chromatography with tandem mass spectrometry, against a GHRP-2 reference standard, found GHRP-2 with the correct sequence at about 50 µg per tablet. The chemical structure printed on the label was wrong: it is not GHRP-2 or any other growth-hormone releasing peptide, and it was not in the tablets. The paper does not give the amount the label claimed, so the 50 µg cannot be judged against it, and it reports no purity. Test date: The paper reports on 'different confiscated products and legally obtained nutritional supplements' that 'were analyzed in 2009'; recorded as 2009.
- LR-0034: A drinking solution sold over the counter as a nutritional supplement in Cyprus, labelled to contain 'active GHRP-2 ester Z11'. Liquid chromatography with tandem mass spectrometry, against a GHRP-2 reference standard, found GHRP-2 itself, about 9 mg in one ampoule (one recommended daily serving). 'GHRP-2 ester Z11' is not a defined molecule, so whether the product held what its label named cannot be judged; the reading is inconclusive. No purity was reported. Test date: The paper reports on 'different confiscated products and legally obtained nutritional supplements' that 'were analyzed in 2009'; recorded as 2009.
- LR-0035: A glass vial of white powder for intranasal use, marked '50 mg Epitalon', seized by the Belgian health authorities. LC-MS/MS and high-resolution mass spectrometry found a peptide of the expected mass (391.1465 measured against 391.1466 for protonated AEDG); de novo sequencing and heat and acid treatment against synthetic reference peptides ruled out the isomer EADG and the isobaric TPCA, leaving AEDG. The paper reports identity only: it measured neither the amount of peptide nor its purity. Where the product was bought is not stated. Test date: The paper does not date the analyses. It says the laboratory received the two samples 'in the last year', and it was first published online on December 22, 2014; recorded as 2014.
- LR-0036: Sublingual tablets sold as a food supplement, marked 'EPITALON' and 3 mg of peptide per tablet, seized by the Belgian health authorities. LC-MS/MS and high-resolution mass spectrometry found the same peptide as in the vial (391.1467 measured against 391.1466 for protonated AEDG), confirmed as AEDG by the same reference-peptide tests. The 3 mg per tablet was not checked. The paper reports identity only: it measured neither the amount of peptide nor its purity. Where the product was bought is not stated. Test date: The paper does not date the analyses. It says the laboratory received the two samples 'in the last year', and it was first published online on December 22, 2014; recorded as 2014.
- LR-0037: The box and vials were intercepted by the Belgian medicines agency (FAMHP) at the end of 2014. An immunoblot against IGF-1, long R3 IGF-1 and R3 IGF-1 gave no signal for the sample; LC-MS/MS of the intact protein gave a mass of 6215.9 Da, matching none of them, and LC-MS/MS of its tryptic digest identified human epidermal growth factor, a cell-culture reagent. The paper gives no amount or purity. The label misspelled its own ingredient ('reconbinant'). Where the vial was bought is not stated. Test date: The paper says the preparation was submitted for analysis 'at the end of 2014'; recorded as 2014.
- LR-0038: A vial of powder labelled Melanotan II, seized by police with a vial of liquid meant to dissolve it. Retention time, UV spectrum and the doubly charged ion matched a purchased melanotan II reference standard on HPLC-DAD and UHPLC-TOF-MS. Where the vial was bought is not stated. Test date: The paper does not date the analysis. It was published in the November 2024 issue of the Journal of Forensic Sciences (online September 20, 2024), so the vial was analysed on or before then; recorded as 2024.
- LR-0039: The vial held 8.7 mg of powder, not the 10 mg on the label, and that powder was 30% melanotan II by HPLC-DAD against a reference-standard calibration curve: 2.61 mg of melanotan II, about a quarter of the labelled amount. No impurity peaks were seen; the authors suggest the rest was inorganic material such as buffers or salts. A dose measured by the label would hold about a quarter of what it claimed. Test date: The paper does not date the analysis. It was published in the November 2024 issue of the Journal of Forensic Sciences (online September 20, 2024), so the vial was analysed on or before then; recorded as 2024.
- LR-0040: Pens presented as Ozempic held insulin glulisine, a fast-acting insulin, with the excipients of an insulin pen and without those of genuine Ozempic; LC-HRMS, NMR and a polypeptide fingerprint agreed. People in Austria who injected these pens were admitted to hospital. Injecting insulin while expecting semaglutide can cause severe hypoglycaemia. The report counts no pens; its figures show two. Where the pens were bought is not stated. Test date: The report does not date the analyses. It was published by CVUA Karlsruhe on November 22, 2023, so the pens were analysed on or before then; recorded as November 2023.
What we searched for
For the compounds people buy most outside licensed pharmacies, we searched PubMed for published tests of products as sold. "None found" means none we could add under the rules above, on the date shown; the queries and the papers read and left out are listed so the search can be repeated.
- ACE-031: searched October 27, 2026, rows added: LR-0029, LR-0030, LR-0031.
Queries
- PubMed record 40312924 (named by queue rows Q897 and Q901), read in full text through PubMed Central (PMC12489275)
- PubMed: (ACE-031 OR ramatercept) AND (black market OR product OR counterfeit OR purchased) -> 3 records; the other two (41686840, 41256654) are a marmoset efficacy study and its preprint, not product tests
- AOD-9604: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: ("AOD-9604" OR "AOD9604" OR "hGH fragment 176-191" OR "HGH 176-191") AND (confiscated OR seized OR "black market" OR counterfeit OR illicit OR internet OR online OR products OR vials) -> 5 records
Read and not added:
- Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. (2014; PMID 24976118). A Belgian seizure was confirmed as AOD9604 by SDS-PAGE and LC-MS/MS, but the vial was labelled as a differently named 2 mg product, not as AOD9604, so there is no AOD9604 claim to test against.
- Detection and in vitro metabolism of AOD9604. (2015; PMID 25208511). Mentions AOD9604 found in confiscated unlabelled vials; the paper itself tests a reference standard, not a product.
- BPC-157: searched October 27, 2026, rows added: LR-0026.
Queries
- PubMed: (BPC-157 OR "BPC 157" OR "body protection compound") AND (purity OR counterfeit OR "black market" OR "illicit" OR "online" OR "grey market" OR "gray market" OR "mass spectrometry" OR "LC-MS" OR seized OR "product analysis") -> 7 records; 28035768 read in full text
- Cerebrolysin: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: (cerebrolysin OR selank OR semax OR "N-acetyl semax" OR noopept OR dihexa) AND (counterfeit OR falsified OR illegal OR seized OR internet OR online OR "black market") AND (analysis OR identified OR "mass spectrometry" OR purity) -> 5 records
Read and not added:
- Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. (2015; PMID 26017115). Peptide profiling of one internet-bought Cerebrolysin sample (638 pig-brain peptides identified, read in full text through Wiley Scholar Gateway); it was not compared with the authorised product or tested for content or purity, so it gives no verdict.
- CJC-1295: searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed: the ipamorelin query above, which names CJC-1295, modified GRF and GRF 1-29 -> 22 records
- PubMed: (GHRP-6 OR GHRP-2 OR hexarelin OR "growth hormone releasing peptide" OR "growth hormone-releasing peptides") AND (confiscated OR seized OR "black market" OR illegal OR counterfeit OR internet OR products OR preparation) AND (mass spectrometry OR identification OR quantification) -> 36 records
- PubMed: ("peptide hormones" OR "peptide drugs" OR "research peptides" OR "research chemicals") AND (internet OR online OR "black market" OR illegal OR falsified OR seized) AND (analysis OR identified OR quantified OR purity OR content) -> 102 records, first 60 screened by title
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
- PubMed (Q1033): "unknown pharmaceutical preparation"[tiab] OR "black market products"[tiab] OR "black market product"[tiab] OR "illegal peptide drugs"[tiab] OR "illegal polypeptide drugs"[tiab] OR "falsified polypeptide"[tiab] OR "peptide preparations"[tiab] -> 153 records, first 60 screened by title
Read and not added:
- Glycine-modified growth hormone secretagogues identified in seized doping material. (2019; PMID 30136411). Seized vials held glycine-extended modified GRF 1-29 (CJC-1295 without DAC plus one glycine), but the vials were unmarked, so there is no label to test against.
- Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. (2017; PMID 28035768). Lists CJC-1295 DAC among the contents of confiscated vials without saying what the vials were labelled or giving data.
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. (2010; PMID 21204297). Norwegian customs and police sample: an unknown preparation held CJC-1295, identified by LC-HRMS/MS, but the paper calls it an unknown pharmaceutical preparation, with no label claim to test against.
- Glycine-modified growth hormone secretagogues identified in seized doping material. (2019; PMID 30136411). Seized powders held glycine-extended analogues of GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29; the abstract calls them unknown preparations and states no label claim to test against.
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. (2010; PMID 21204297). Norwegian police and customs submitted an 'unknown pharmaceutical preparation' that held CJC-1295 (modified GRF 1-29); there was no label claim to test against.
- Epithalon: searched October 27, 2026, rows added: LR-0035, LR-0036.
Queries
- PubMed: (Deconinck E[Author] OR Janvier S[Author] OR Krug O[Author] OR Walpurgis K[Author]) AND (peptide OR peptides OR melanotan OR GHRP OR "IGF-1") -> 81 records, first 40 screened by title; and Vanhee C[Author] AND (peptide OR peptides) -> 11 records
- PubMed record 25535022 read in full text through Wiley Scholar Gateway
- Follistatin-344: searched October 27, 2026, rows added: LR-0024, LR-0025.
Queries
- PubMed record 31758732 (named by queue row Q897), read in full text through Wiley Scholar Gateway
- GHK-Cu: searched October 27, 2026, none found.
Queries
- PubMed: ("GHK-Cu" OR "copper peptide" OR "copper tripeptide" OR "GHK copper") AND (cosmetic products OR serums OR creams OR products OR online) AND (HPLC OR "mass spectrometry" OR quantification OR content OR determination) -> 31 records; none tested a GHK-Cu product as sold (formulation, liposome and assay-method studies only)
- PubMed: ("GHK-Cu" OR "copper tripeptide-1" OR "copper peptide") AND (counterfeit OR illicit OR "black market" OR internet OR "injectable" OR "research chemical") AND (identity OR "mass spectrometry" OR analysis) -> 1 record, a hair-growth formulation study, not a product test
- GHRP-2: searched November 3, 2026, rows added: LR-0033, LR-0034.
Queries and papers read and not added
- PubMed: (GHRP-6 OR GHRP-2 OR hexarelin OR "growth hormone releasing peptide" OR "growth hormone-releasing peptides") AND (confiscated OR seized OR "black market" OR illegal OR counterfeit OR internet OR products OR preparation) AND (mass spectrometry OR identification OR quantification) -> 36 records
- PubMed: ("GHRP-6" OR hexarelin OR ipamorelin OR "GHRP-2" OR pralmorelin) AND (supplement OR supplements OR "nutritional supplement" OR "doping products" OR "lifestyle drugs" OR vial OR vials) -> 9 records
- PubMed record 21204286 read in full text through Wiley Scholar Gateway
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
- PubMed (Q1033): "unknown pharmaceutical preparation"[tiab] OR "black market products"[tiab] OR "black market product"[tiab] OR "illegal peptide drugs"[tiab] OR "illegal polypeptide drugs"[tiab] OR "falsified polypeptide"[tiab] OR "peptide preparations"[tiab] -> 153 records, first 60 screened by title
Read and not added:
- Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. (2010; PMID 20878896). The same tablets as LR-0033, quantified by the same laboratory at about 50 µg GHRP-2 per tablet; the abstract does not give the label's claimed amount, so it adds no verdict beyond LR-0033.
- Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial. (2019; PMID 30051972). A seized injection vial held a glycine analogue of GHRP-2, a different molecule; the abstract does not say what the vial was labelled.
- Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: a case-report. (2014; PMID 24446112). GHRP-2 identified and quantified in seized unlabelled vials, so there is no label claim to test against.
- Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: a case-report. (2014; PMID 24446112). GHRP-2 identified and quantified by NMR and MS in seized vials that the title describes as unlabelled, so there is no label claim to test against.
- GHRP-6: searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed: (GHRP-6 OR GHRP-2 OR hexarelin OR "growth hormone releasing peptide" OR "growth hormone-releasing peptides") AND (confiscated OR seized OR "black market" OR illegal OR counterfeit OR internet OR products OR preparation) AND (mass spectrometry OR identification OR quantification) -> 36 records
- PubMed: ("GHRP-6" OR hexarelin OR ipamorelin OR "GHRP-2" OR pralmorelin) AND (supplement OR supplements OR "nutritional supplement" OR "doping products" OR "lifestyle drugs" OR vial OR vials) -> 9 records
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
- PubMed (Q1033): "unknown pharmaceutical preparation"[tiab] OR "black market products"[tiab] OR "black market product"[tiab] OR "illegal peptide drugs"[tiab] OR "illegal polypeptide drugs"[tiab] OR "falsified polypeptide"[tiab] OR "peptide preparations"[tiab] -> 153 records, first 60 screened by title
Read and not added:
- Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. (2017; PMID 28156209). 1,190 doping products seized at the Swiss border, 146 labelled as peptide hormones or growth factors; fewer than 20% held the claimed substance in the claimed amount, but the per-product results are not in the abstract and the full text could not be read.
- Identification of black market products and potential doping agents in Germany 2010-2013. (2014; PMID 25168622). 337 black-market products analysed in Cologne 2010-2013 (12.8% peptide hormones, mainly hGH and GHRPs); the abstract gives no per-product label claims and the full text could not be read.
- Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. (2018; PMID 30029448). Belgian OMCL survey of the ten most frequent falsified peptide drugs bought from three illegal internet pharmacies: the abstract gives purity of 5 to 75% for cysteine-containing peptides without saying which compound or product, and the full text (Talanta) could not be read.
- Glycine-modified growth hormone secretagogues identified in seized doping material. (2019; PMID 30136411). Seized powders held glycine-extended analogues of GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29; the abstract calls them unknown preparations and states no label claim to test against.
- Hexarelin: searched October 27, 2026, rows added: LR-0032.
Queries and papers read and not added
- PubMed: (GHRP-6 OR GHRP-2 OR hexarelin OR "growth hormone releasing peptide" OR "growth hormone-releasing peptides") AND (confiscated OR seized OR "black market" OR illegal OR counterfeit OR internet OR products OR preparation) AND (mass spectrometry OR identification OR quantification) -> 36 records
- PubMed: ("GHRP-6" OR hexarelin OR ipamorelin OR "GHRP-2" OR pralmorelin) AND (supplement OR supplements OR "nutritional supplement" OR "doping products" OR "lifestyle drugs" OR vial OR vials) -> 9 records
- PubMed record 21204286 read in full text through Wiley Scholar Gateway
Read and not added:
- Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. (2017; PMID 28156209). 1,190 doping products seized at the Swiss border, 146 labelled as peptide hormones or growth factors; fewer than 20% held the claimed substance in the claimed amount, but the per-product results are not in the abstract and the full text could not be read.
- Identification of black market products and potential doping agents in Germany 2010-2013. (2014; PMID 25168622). 337 black-market products analysed in Cologne 2010-2013 (12.8% peptide hormones, mainly hGH and GHRPs); the abstract gives no per-product label claims and the full text could not be read.
- IGF-1 LR3: searched November 3, 2026, rows added: LR-0037. Q1033 read 27390261 in full: its Figure 1 shows the vial was labelled 'reconbinant IGF-1 long R3', a label claim the Q897 screening could not see from the title, so the paper is now row LR-0037 and no longer listed as read and not added.
Queries and papers read and not added
- PubMed: ("long R3 IGF-1" OR "LR3-IGF-1" OR "long-R3" OR "IGF-1 LR3" OR mecasermin OR "insulin-like growth factor") AND (confiscated OR seized OR "black market" OR counterfeit OR illicit OR internet) AND (products OR vials OR preparation) -> 15 records
- PubMed (Q1033): (IGF-1 OR "insulin-like growth factor" OR "growth hormone" OR somatropin OR "hGH fragment") AND ("black market" OR counterfeit OR seized OR confiscated OR internet) AND (products OR preparations OR vials) AND (analysis OR identified OR mass) -> 38 records
- PubMed record 27390261 read in full text through Wiley Scholar Gateway (Q1033)
Read and not added:
- Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. (2010; PMID 21204286). Three confiscated vials held long-R3-IGF-1 (one mostly an unpurified His-tagged form), but all three were unlabelled, so there is no label claim to test against.
- Detection of His-tagged Long-R³-IGF-I in a black market product. (2010; PMID 20675162). Case report of His-tagged long-R3-IGF-1 found in an injection vial, the vial 21204286 lists as unlabelled (its product 1d, citing this report); the abstract gives no label claim to test against.
- Ipamorelin: searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed: (ipamorelin OR "CJC-1295" OR "CJC 1295" OR "modified GRF" OR "mod GRF" OR "GRF 1-29" OR sermorelin OR tesamorelin) AND (confiscated OR seized OR "black market" OR counterfeit OR illicit OR internet OR online OR vials OR products) AND (mass spectrometry OR identification OR identified OR characterization) -> 22 records
- PubMed: ("GHRP-6" OR hexarelin OR ipamorelin OR "GHRP-2" OR pralmorelin) AND (supplement OR supplements OR "nutritional supplement" OR "doping products" OR "lifestyle drugs" OR vial OR vials) -> 9 records
- PubMed: ("peptide hormones" OR "peptide drugs" OR "research peptides" OR "research chemicals") AND (internet OR online OR "black market" OR illegal OR falsified OR seized) AND (analysis OR identified OR quantified OR purity OR content) -> 102 records, first 60 screened by title
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
- PubMed (Q1033): "unknown pharmaceutical preparation"[tiab] OR "black market products"[tiab] OR "black market product"[tiab] OR "illegal peptide drugs"[tiab] OR "illegal polypeptide drugs"[tiab] OR "falsified polypeptide"[tiab] OR "peptide preparations"[tiab] -> 153 records, first 60 screened by title
Read and not added:
- Glycine-modified growth hormone secretagogues identified in seized doping material. (2019; PMID 30136411). Danish customs seizures held glycine-extended ipamorelin (Gly-ipamorelin), a different molecule, but those vials were unmarked or labelled as a vitamin, so there is no ipamorelin label to test against.
- Analysis of new growth promoting black market products. (2018; PMID 29864719). Found Gly-ipamorelin in black-market products; the abstract does not say what the products were sold as, and the full text could not be read.
- Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. (2017; PMID 28035768). Lists ipamorelin among the contents of confiscated vials without saying what those vials were labelled or giving data.
- Glycine-modified growth hormone secretagogues identified in seized doping material. (2019; PMID 30136411). Seized powders held glycine-extended analogues of GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29; the abstract calls them unknown preparations and states no label claim to test against.
- Analysis of new growth promoting black market products. (2018; PMID 29864719). Black-market products held Gly-ipamorelin, Gly-GHRP-2 and Gly-GHRP-6 and an alanine-extended growth hormone; the abstract states no label claim for any product.
- Melanotan II: searched November 3, 2026, rows added: LR-0017, LR-0018, LR-0019, LR-0038, LR-0039.
Queries and papers read and not added
- PubMed (Q1033): (melanotan[tiab]) AND (internet OR online OR purchased OR products OR vials OR content OR purity) -> 52 records
- PubMed records 24771717 (rows LR-0017 to LR-0019, Q891) and 39302005 (read in full text through Wiley Scholar Gateway, rows LR-0038 and LR-0039)
Read and not added:
- LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. (2021; PMID 33245851). Italian police seizure: four of eight vials held melanotan II, identified by LC-HRMS, but all eight vials were unlabelled (read in full text through Wiley Scholar Gateway), so there is no label claim to test against.
- MGF: searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
- PubMed (Q1033): "unknown pharmaceutical preparation"[tiab] OR "black market products"[tiab] OR "black market product"[tiab] OR "illegal peptide drugs"[tiab] OR "illegal polypeptide drugs"[tiab] OR "falsified polypeptide"[tiab] OR "peptide preparations"[tiab] -> 153 records, first 60 screened by title
Read and not added:
- Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. (2012; PMID 22328223). Two black-market preparations held a C-terminally amidated analogue of human MGF; the abstract describes them as preparations containing an unknown MGF analogue and states no label claim.
- MK-677: searched November 3, 2026, rows added: LR-0028.
Queries and papers read and not added
- PubMed: (ibutamoren OR "MK-677" OR "MK 677" OR MK0677) AND (products OR supplements OR internet OR online OR label OR labeling OR purchased OR "black market") -> 26 records
- PubMed: Leaney[Author] AND (SARMs OR "selective androgen receptor modulators") AND products -> 1 record (32748554), read in full text
- PubMed (Q1033): (peptide OR peptides) AND ("black market" OR "grey market" OR "gray market" OR "research chemical" OR "research chemicals" OR internet OR seized OR confiscated) AND (identified OR identification OR "mass spectrometry" OR purity OR characterization) AND (doping OR products OR vials), 2010 on -> 161 records, first 60 screened by title
Read and not added:
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. (2017; PMID 29183075). JAMA 2017: 44 products sold as SARMs; ibutamoren was among the undeclared drugs found, but the per-product table is not in the abstract and the full text could not be read, so no row states what a product declaring ibutamoren held.
- SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON. (2025; PMID 40551438). GEON 2025 seizure study: ibutamoren was the most reported molecule (62 reports) with 4 to 25 mg per capsule or tablet and 0.4 to 262.6 mg/mL in liquids, but the paper gives no product count for those ranges and no label claim per product, so a row could not state how many vials it covers or what each was meant to hold.
- SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON. (2025; PMID 40551438). European OMCL network survey (GEON) of 324 suspected illegal samples over five years: ibutamoren was the most reported molecule, but the abstract gives no per-product label claim against a measured amount.
- Noopept: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: (cerebrolysin OR selank OR semax OR "N-acetyl semax" OR noopept OR dihexa) AND (counterfeit OR falsified OR illegal OR seized OR internet OR online OR "black market") AND (analysis OR identified OR "mass spectrometry" OR purity) -> 5 records
Read and not added:
- The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. (2025; PMID 40558871). GEON and TGA market survey of illicit nootropics (read in full text in PubMed Central): noopept was found mostly as bulk raw material, up to 100% pure, and once at 20 mg/mL, but no per-product label claim is given to judge it against.
- PT-141: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: (melanotan OR "melanotan II" OR bremelanotide OR "PT-141" OR afamelanotide) AND (internet OR online OR illegal OR "black market" OR seized OR products OR vials OR purchased) AND (purity OR content OR "mass spectrometry" OR HPLC OR analysis) -> 31 records
Read and not added:
- LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. (2021; PMID 33245851). Italian police seizure: four of eight vials held bremelanotide, identified by LC-HRMS, but all eight vials were unlabelled (read in full text through Wiley Scholar Gateway), so there is no label claim to test against.
- Retatrutide: searched October 27, 2026, none found. No new measurement beyond the rows already held (PMID 42559975).
Queries and papers read and not added
- PubMed: the semaglutide query above, which names retatrutide -> 21 records
- PubMed: (semaglutide OR tirzepatide OR retatrutide) AND (unlicensed OR "illegal online" OR "online pharmacies" OR "research use only" OR falsified OR counterfeit OR "test purchase" OR compounded) AND (analysed OR analyzed OR purity OR "mass spectrometry" OR HPLC OR endotoxin) -> 18 records
- PubMed: (tirzepatide[tiab] OR semaglutide[tiab] OR retatrutide[tiab]) AND ("research grade"[tiab] OR "research peptide"[tiab] OR "research peptides"[tiab] OR "gray market"[tiab] OR "grey market"[tiab] OR "online vendors"[tiab] OR "illegal online"[tiab] OR unlicensed[tiab]) -> 5 records, none an analysis of a product
Read and not added:
- Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. (2026; PMID 42669023). Case report of an online-bought product sold as retatrutide; the authors state it was not analysed.
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. (2026; PMID 42843917). Case report of injections 'reported to contain retatrutide' given in a wellness setting; the product was not analysed.
- Selank: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: (cerebrolysin OR selank OR semax OR "N-acetyl semax" OR noopept OR dihexa) AND (counterfeit OR falsified OR illegal OR seized OR internet OR online OR "black market") AND (analysis OR identified OR "mass spectrometry" OR purity) -> 5 records
Read and not added:
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. (2020; PMID 31667971). Seized preparations held selank and semax, but they were 'unknown suspicious preparations', so there is no label claim to test against.
- Semaglutide: searched November 3, 2026, rows added: LR-0040. Rows from PMIDs 39509151 and 42533250 were already held; Q1033 added the CVUA Karlsruhe finding (LR-0040), a regulator's own laboratory result.
Queries and papers read and not added
- PubMed: (semaglutide[tiab] OR retatrutide[tiab]) AND (counterfeit[tiab] OR falsified[tiab] OR illegal[tiab] OR illicit[tiab] OR "online"[tiab] OR "research use"[tiab] OR unlicensed[tiab]) AND (LC-MS[tiab] OR HPLC[tiab] OR "mass spectrometry"[tiab] OR purity[tiab] OR endotoxin[tiab] OR analysed[tiab] OR analyzed[tiab]) -> 21 records
- PubMed: (semaglutide OR tirzepatide OR retatrutide) AND (unlicensed OR "illegal online" OR "online pharmacies" OR "research use only" OR falsified OR counterfeit OR "test purchase" OR compounded) AND (analysed OR analyzed OR purity OR "mass spectrometry" OR HPLC OR endotoxin) -> 18 records
- PubMed: (tirzepatide[tiab] OR semaglutide[tiab] OR retatrutide[tiab]) AND ("research grade"[tiab] OR "research peptide"[tiab] OR "research peptides"[tiab] OR "gray market"[tiab] OR "grey market"[tiab] OR "online vendors"[tiab] OR "illegal online"[tiab] OR unlicensed[tiab]) -> 5 records, none an analysis of a product
- FDA: 'FDA's concerns with unapproved GLP-1 drugs used for weight loss' (last updated October 1, 2026), read with WebFetch: it says FDA 'is aware that some semaglutide products sold by compounders may be the salt forms' but reports no test result
- FDA: 'FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain' (December 21, 2023; updates April 14 and December 5, 2025), read with WebFetch: counterfeit needles, labels and cartons confirmed, but the drug's 'identity, quality or safety' still under test; no content result
- FDA: warning letter to a research-peptide seller of semaglutide and tirzepatide (December 10, 2024), read with WebFetch: based on a website review, no FDA sample analysis
- TGA: safety alert on counterfeit weight-loss products claiming to contain GLP-1, found through WebSearch; the page could not be read (the site refuses automated reading), and the news report of it says the products held no GLP-1 analogue but names none as semaglutide or tirzepatide and gives no method
- MHRA: WebSearch for laboratory analyses of seized weight-loss pens (2025-2026) found raid and seizure notices but no published test result
- PubMed (Q1033): (semaglutide[tiab] OR tirzepatide[tiab] OR retatrutide[tiab] OR "GLP-1 receptor agonist"[tiab]) AND (counterfeit[tiab] OR falsified[tiab] OR illegal[tiab] OR illicit[tiab] OR "research use"[tiab] OR "research peptide"[tiab] OR "online"[tiab] OR unlicensed[tiab] OR "gray market"[tiab] OR "grey market"[tiab] OR compounded[tiab]) AND (analysis[tiab] OR analyzed[tiab] OR analysed[tiab] OR tested[tiab] OR purity[tiab] OR content[tiab]) -> 93 records, first 80 screened by title
- Regulators (Q1033): WebSearch for regulator laboratory results on falsified GLP-1 pens (TGA, MHRA, HPRA, EDQM/OMCL); read with WebFetch the EDQM-hosted CVUA Karlsruhe report of November 22, 2023 and the EDQM notice 'OMCL confirms falsification of Ozempic batches' (row LR-0040). A news report of a TGA alert (October 31, 2024) says the seized pens 'are currently undergoing laboratory testing' and reports no result; MHRA notices found report seizures and hospitalisations, not test results.
Read and not added:
- Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. (2026; PMID 41773123). Case report of an online-bought semaglutide pen; the product was not analysed.
- Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. (2024; PMID 39379664). Novo Nordisk analysis of 16 injectable and 8 oral follow-on semaglutide products: several oral products held markedly less semaglutide than claimed, but the abstract gives no per-product figures, does not say which products were sold outside licensed pharmacies, and the full text could not be read.
- Hypoglycaemic coma induced by a falsified semaglutide product: a case report. (2026; PMID 41125326). Case report: a vial bought online as semaglutide (Ozempic) held insulin instead, by 'toxicological analysis'. The abstract names no method and no amount, and the full text could not be read, so no row can carry a method; the finding is cited on /verify/fake-coa-red-flags/.
- Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. (2026; PMID 41773123). Case report of ketoacidosis after semaglutide bought online; the product itself was not analysed.
- Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. (2024; PMID 39379664). 16 injectable and 8 oral follow-on semaglutide products tested against the originator; the abstract reports new impurities and oral products with markedly less semaglutide than labelled but gives no per-product figures, and the full text could not be read.
- Semax: searched October 27, 2026, none found.
Queries and papers read and not added
- PubMed: (cerebrolysin OR selank OR semax OR "N-acetyl semax" OR noopept OR dihexa) AND (counterfeit OR falsified OR illegal OR seized OR internet OR online OR "black market") AND (analysis OR identified OR "mass spectrometry" OR purity) -> 5 records
Read and not added:
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. (2020; PMID 31667971). Seized preparations held selank and semax, but they were 'unknown suspicious preparations', so there is no label claim to test against.
- Somatropin (HGH): searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed (Q1033): (IGF-1 OR "insulin-like growth factor" OR "growth hormone" OR somatropin OR "hGH fragment") AND ("black market" OR counterfeit OR seized OR confiscated OR internet) AND (products OR preparations OR vials) AND (analysis OR identified OR mass) -> 38 records
Read and not added:
- Availability and quality of illegitimate somatropin products obtained from the Internet. (2017; PMID 27888454). Somatropin bought from websites selling without prescription (June to August 2014): the abstract says all samples held significantly less somatropin than labelled (capillary electrophoresis with UV and ESI-MS) but gives neither the number of products nor any measured amount, and the full text could not be read, so no row can state a figure.
- TB-500: searched October 27, 2026, rows added: LR-0027.
Queries
- PubMed: ("TB-500" OR "TB500" OR "thymosin beta 4" OR "thymosin beta-4" OR "Ac-LKKTETQ") AND (confiscated OR seized OR "black market" OR counterfeit OR illicit OR "online" OR "product" OR vial) AND (mass spectrometry OR identification OR purity) -> 10 records; 22962027 read in full text
- Tirzepatide: searched November 3, 2026, none found.
Queries and papers read and not added
- PubMed: tirzepatide[tiab] AND (counterfeit[tiab] OR falsified[tiab] OR "research use"[tiab] OR illegal[tiab] OR illicit[tiab] OR "online"[tiab] OR "test purchase"[tiab] OR "without a prescription"[tiab] OR compounded[tiab]) AND (HPLC[tiab] OR "mass spectrometry"[tiab] OR LC-MS[tiab] OR analysed[tiab] OR analyzed[tiab] OR purity[tiab] OR content[tiab] OR endotoxin[tiab]) -> 11 records, none an analysis of a product (surveys, pharmacovigilance, advertising studies)
- PubMed: (semaglutide OR tirzepatide OR retatrutide) AND (unlicensed OR "illegal online" OR "online pharmacies" OR "research use only" OR falsified OR counterfeit OR "test purchase" OR compounded) AND (analysed OR analyzed OR purity OR "mass spectrometry" OR HPLC OR endotoxin) -> 18 records
- PubMed: (tirzepatide[tiab] OR semaglutide[tiab] OR retatrutide[tiab]) AND ("research grade"[tiab] OR "research peptide"[tiab] OR "research peptides"[tiab] OR "gray market"[tiab] OR "grey market"[tiab] OR "online vendors"[tiab] OR "illegal online"[tiab] OR unlicensed[tiab]) -> 5 records, none an analysis of a product
- FDA: 'FDA's concerns with unapproved GLP-1 drugs used for weight loss' (last updated October 1, 2026), read with WebFetch: it says FDA 'is aware that some semaglutide products sold by compounders may be the salt forms' but reports no test result
- FDA: 'FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain' (December 21, 2023; updates April 14 and December 5, 2025), read with WebFetch: counterfeit needles, labels and cartons confirmed, but the drug's 'identity, quality or safety' still under test; no content result
- FDA: warning letter to a research-peptide seller of semaglutide and tirzepatide (December 10, 2024), read with WebFetch: based on a website review, no FDA sample analysis
- TGA: safety alert on counterfeit weight-loss products claiming to contain GLP-1, found through WebSearch; the page could not be read (the site refuses automated reading), and the news report of it says the products held no GLP-1 analogue but names none as semaglutide or tirzepatide and gives no method
- MHRA: WebSearch for laboratory analyses of seized weight-loss pens (2025-2026) found raid and seizure notices but no published test result
- PubMed (Q1033): (semaglutide[tiab] OR tirzepatide[tiab] OR retatrutide[tiab] OR "GLP-1 receptor agonist"[tiab]) AND (counterfeit[tiab] OR falsified[tiab] OR illegal[tiab] OR illicit[tiab] OR "research use"[tiab] OR "research peptide"[tiab] OR "online"[tiab] OR unlicensed[tiab] OR "gray market"[tiab] OR "grey market"[tiab] OR compounded[tiab]) AND (analysis[tiab] OR analyzed[tiab] OR analysed[tiab] OR tested[tiab] OR purity[tiab] OR content[tiab]) -> 93 records, first 80 screened by title
Read and not added:
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. (2026; PMID 42010938). Scientists at tirzepatide's maker report a new impurity formed between tirzepatide and some vitamin B12 analogues in compounded tirzepatide/B12 products, but the abstract gives no per-sample amounts, sample count or test dates, and the full text is not open access, so no result row can be built (read October 27, 2026, Q913).
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. (2026; PMID 42010938). Compounded tirzepatide combined with vitamin B12, bought in the US: a new impurity formed by reaction between the two. The abstract gives no number of samples and no amount, and the full text could not be read.
Read and not added
Studies we screened that do not meet the rules yet. They are listed so that leaving them out is visible, not silent.
- Janvier S et al. Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs. Drug Test Anal 2018. Sterility tests on 100 illegal injectable peptide samples (40 seized, 60 bought from three internet sites selling research chemicals): two vials from one site grew haemolytic Bacillus cereus. Not added: the passages we could read do not say which peptides the two contaminated vials held, so no row can carry a compound.
- Janvier S et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 2018. Ten falsified peptide drugs bought from three suspected illegal internet pharmacies: purity 5% to 75% for cysteine-containing peptides, arsenic up to ten times the ICH limit for injectables, lead in one sample. Not added: only the abstract could be read, and it gives these figures across products, not per compound.